Physicians need to make appropriate antimicrobial choices fortherapy when faced with community acquired pneumonia (CAP), especially if levels of quinolone resistant streptococcus pneumoniae (QRSP) continue to rise.
That was the conclusion of a study presented by Dr. Mendel Singer, MD, of the Case Western University School of Medicine in Cleveland, OH, during the Interscience Conference on Antimicrobial Agents and Chemotherapy.
“The worldwide increase in antibacterial resistance presents a formidable problem for the treatment of community acquired respiratory tract infections,” Dr. Singer said.
Among other difficulties, there is cross-resistance among classes of drugs, especially the macrolides, lincosamides and streptogramins B. CAP is a serious and common disease, linked to significant morbidity and mortality; most cases of CAP are bacterial and the most frequent culprit is S. pneumoniae.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!